Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes
This activity is supported through educational grants from AstraZeneca, Mersana Therapeutics, and Novocure.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing medical education activity is jointly provided by American Academy of CME, Inc. and National Ovarian Cancer Coalition (NOCC).
Release date: 06/15/2023
Expiration date: 06/15/2024
Activity Description
Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by oncology care team members to increase awareness of disparities among Black women with ovarian cancer and potential actions the team can take to reduce them.
Support Statement
This activity is supported through educational grants from AstraZeneca, Mersana Therapeutics, and Novocure.
Target Audience
This activity is designed for medical oncologists, oncology gynecologists, oncology APPs, oncology nurses and oncology pharmacists engaged in the care of patients with ovarian cancer. Other healthcare professionals may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the impact of ovarian cancer on Black women and disparities in outcomes
- Consider interprofessional opportunities to improve communication around risk factors and risk assessment for Black women
- Assess the role of interprofessional team in aligning treatment of ovarian cancer in Black women with current standards of care
Faculty
Paula J. Anastasia, MN, RN, AOCN
Patient and Oncology Nurse Education Consultant
Joan R. Tymon-Rosario, MD
Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Zucker School of Medicine
Northwell Health Cancer Institute
David P. Warshal, MD
Head, Division of Gynecologic Oncology
MD Anderson Cancer Center at Cooper
Professor of Obstetrics and Gynecology
Cooper Medical School of Rowan University
Clinical Reviewer
Val Adams, PharmD
Associate Professor, College of Pharmacy
Lucille Parker Markey Cancer Center
University of Kentucky
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and National Ovarian Cancer Coalition (NOCC). American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
This activity provides 1.50 ACPE contact hours (0.150 CEUs) of continuing education credit. Universal Activity Number JA4008191-9999-23-016-H01-P. Knowledge
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this enduring educational activity for 1.50 ANCC contact hours (0.10 pharmacotherapeutic contact hours).
California: Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.5 contact hours.
Physician Assistants and Other Team Members
A certificate of completion will be provided.
How to Participate in this Activity and Obtain CME/CE Credit
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE/CPE credit, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.
For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.
Disclosures
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all the relevant financial relationships listed for these individuals have been mitigated.
Faculty
Paula J. Anastasia, MN, RN, AOCN discloses the following relevant financial relationships with ineligible companies: Advisory Board/Consultant: Merck; Speaker's Bureau: Genentech*, SeaGen* (*relationship has ended)
Joan R. Tymon-Rosario, MD: No relevant financial relationships with ineligible companies to disclose.
David P. Warshal, MD: No relevant financial relationships with ineligible companies to disclose.
Planning Committee
John JD Juchniewicz, MCIS, CHCP, FACEHP, Wendy Gloffke, PhD, Natalie Kirkwood RN, BSN, JD, and Paul J. Miniter, MS, American Academy of CME: No relevant financial relationships with ineligible companies to disclose.
Vanda Soldati, MS, BSN, RN, CCRN, National Ovarian Cancer Coalition: No relevant financial relationships with ineligible companies to disclose.
Clinical Reviewer
Val Adams, PharmD discloses the following relevant financial relationships with ineligible companies: Advisory Board/Consultant: Bristol Myers Squibb*; Grant/Research Support: Bristol Myers Squibb* (*relationship has ended)
This activity does not include discussion of investigational drugs and/or off-label usage.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or NOCC. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
Implicit Bias
Implicit bias refers to unconscious attitudes and stereotypes that influence our thoughts, judgements, decisions, and actions without our awareness. Everyone is susceptible to implicit bias, even clinicians. In healthcare, implicit biases can have a significant impact on the quality of care an individual receives. These biases can be both favorable and unfavorable, and are activated involuntarily without an individual’s awareness or intentional control. Studies have indicated that healthcare providers’ incorrect perceptions can impact providers’ communications and clinical decision-making contributing to disparities in clinical outcomes. Addressing implicit biases in healthcare is critical to improving health outcomes and promoting health equity for all patients. Patient-centered care can reduce the impact of implicit bias, by treating each patient as a unique individual who may or may not hold beliefs associated with their backgrounds and circumstances. In addition, recognizing implicit bias in one’s own practice using techniques such as self-reflection and mindful clinical decision-making can ensure more equitable and effective care to all patients.
Over the past several decades, cognitive science research has demonstrated human behavior, beliefs and attitudes are shaped by automatic and unconscious cognitive processes. The healthcare profession is devoting greater attention to how these automatic and unconscious processes impact care including: (1) preferential treatment toward or against specific patient populations causing healthcare inequities, (2) influence patient-provider communications leading to misunderstandings and mistrust, and (3) impact access to healthcare and affect treatment decisions resulting in misdiagnosis, delays in treatment and specialty referrals and poor pain management. Considering one might have unconscious biases and exploring them may be uncomfortable because the very idea that they exist may conflict with how clinicians perceive themselves. It is only by becoming aware of one’s unconscious biases that members of the healthcare team can take steps to mitigate them to ensure all their patients are treated receive quality healthcare.
Hardware/Software Requirements
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2023. This accredited continuing education activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
About the National Ovarian Cancer Coalition (NOCC)
The National Ovarian Cancer Coalition (NOCC) is a national not-for-profit established in 1991, with a mission that began as a grassroots effort to raise awareness to now being a major force in the United States working to save lives through the prevention and cure of ovarian cancer and to improve the quality of life for patients / survivors and their caregivers. In 2020, there were an estimated 236,511 women living with ovarian cancer in the United States.